CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 30 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01766076
NCT01766076Phase 3Completed
CompareCT.gov

Use of Atorvastatin as Adjuvant Therapy Among Suboptimal Responders to Antiretroviral Therapy in an African Cohort of HAART-treated Adults: A Randomised Controlled Trial

Makerere University·interventional·Posted Jan 11, 2013·Updated May 21, 2015

In Brief

A Phase 3 clinical trial evaluating atorvastatin, Lipitor® and Placebo for Acquired Immune Deficiency Syndrome Virus. Completed, enrolled 30 participants.

Detailed Summary

We hypothesise that atorvastatin changes immune activation among HAART-treated adults with suboptimal cluster cell differentiation 4 (CD4) recovery by 25%

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcquired Immune Deficiency Syndrome Virus
Countries--
CollaboratorsVaccine and Gene Therapy Institute, Florida

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 11, 2013
Enrollment StartJan 1, 2013
Primary CompletionFeb 1, 2014
Study CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.5 years ago

Interventions

atorvastatin, Lipitor®other

PBMC collected for immune activation assays using flowcytometry

Placebodrug

PBMC collected for immune activation assays using flowcytometry